Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

AstraZeneca Add to portfolio

NYA:AZN, Feb 28, 11:43 UTC

Latest NYA:AZN News

Filter your feed

Apply Filter

Yesterday


News

Chronic Lymphocytic Leukemia Market, Forecast to 2025 - Roche, AstraZeneca, Verastem, Novartis, and AbbVie are Dominating

AZN AZN +1 more AZN AZN ABBV

Chronic Lymphocytic Leukemia Market, Forecast to 2025 - Roche, AstraZeneca, Verastem, Novartis, and AbbVie are Dominating. DUBLIN, Feb. 27, 2020 /PRNewswire/ -- The "Chronic Lymphocytic Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The parenteral route of administration segment is expected to witness the largest market revenue share in recent years and expected to do so over the forecast period. By Treatment, Chemotherapy accounts for its largest market share due to its access from decades and owing to the wide range of products that are available in the market contributing to the growth of the market. North America is Expected to Dominate the MarketNorth America is expected to dominate the overall chronic lymphocytic leukemia market throughout the forecast period.A steep rise in incidences of various cancers with the rapid growth of elder individuals. For instance, according to the report published by the American Cancer Society in January 2020, the risk of CLL increases with a rise in the age and estimates that about 9 out of 10 people with CLL are over age 50 which directly drives for growth of the CLL market.Also, an increase in the approvals from regulatory bodies along with ongoing research activities by the major companies in the United States are likely to contribute the largest share of revenue in the region propelling the global chronic lymphocytic leukemia market.Competitive LandscapeThe Chronic lymphocytic leukemia market is moderately competitive and consists of several major players.Few of the key players are developing the biosimilars to the existing chemotherapies while others are launching the generic products trending in the market. For instance, in November 2019, AstraZeneca PLC received US Food and Drug Administration (FDA) approval for its Calquence (acalabrutinib) to treat adult patients with CLL which is expected to impel the global Chronic lymphocytic leukemia market growth throughout the forecast period.Furthermore, few key players are entering into partnerships to develop and increase their market position globally.

Read Full Details

Topics:
  • Business
  • Health

Tuesday, February 25


News

AstraZeneca sells rights for constipation drug to RedHill Biopharma

AZN AZN

AstraZeneca sells rights for constipation drug to RedHill Biopharma. AstraZeneca will retain rights to sell Movantik in Europe, Canada and Israel. AstraZeneca PLC (LON:AZN) has sold the rights to its drug Movantik to RedHill Biopharma for US$67mln. The treatment, used in patients suffering from constipation caused by painkillers, generated sales of US$96mln in the US alone last year.READ: AstraZeneca revenues surge ahead but coronavirus clouds current year. The FTSE 100-listed firm has already divested the rights to sell the drug in Europe, Canada and Israel while the transaction, scheduled to complete in the first quarter, is not expected to hit guidance for 2020. “This divestment supports our strategy to realise value from medicines in our portfolio that are mature or outside our current scope to enable reinvestment in our main therapy areas,” said Ruud Dobber, executive vice president at AstraZeneca’s biopharmaceuticals business unit. Shares were flat at 7,416p on Tuesday morning.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Entertainment
News

RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca

AZN AZN

“The acquisition of Movantik® is a transformative event for RedHill. We would like to thank AstraZeneca for entrusting us with this important product,” saidDror Ben-Asher, RedHill’s Chief Executive Officer. RedHill promotes the gastrointestinal drug Aemcolo® in the U.S. and is planning to launch Talicia®in the U.S. for the treatment of Helicobacter pylori (H. pylori) infection in adults. Such risks and uncertainties include, without limitation, risks related to the timing for the launch of Talicia® as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its therapeutic candidates and its FDA-approved products; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Talicia®, Aemcolo®, and following closing of the acquisition, Movantik®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; (xv) the hiring and employment commencement date of executive managers; and (xvi) whether the proposed acquisition of Movantik® will be consummated or as to the timing thereof.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, February 24


News

The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, AstraZeneca and Duke Energy

AZN JPM +4 more AZN JPM AZN DUK BAC V

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa V, JPMorgan Chase JPM, Bank of America BAC, AstraZeneca AZN and Duke Energy DUK. The Zacks analyst believes that shift in payments to new methods, such as mobile, cards, online and via wearables bodes well for the long haul. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Bank of America Corporation (BAC) : Free Stock Analysis Report AstraZeneca PLC (AZN) : Free Stock Analysis Report Duke Energy Corporation (DUK) : Free Stock Analysis Report Visa Inc. (V) : Free Stock Analysis Report To read this article on Zacks.com click here.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, February 23


News

Why It Might Not Make Sense To Buy AstraZeneca PLC (LON:AZN) For Its Upcoming Dividend

AZN AZN

Based on the last year's worth of payments, AstraZeneca has a trailing yield of 2.8% on the current stock price of £76.9. If you buy this business for its dividend, you should have an idea of whether AstraZeneca's dividend is reliable and sustainable. So we need to investigate whether AstraZeneca can afford its dividend, and if the dividend could grow. A useful secondary check can be to evaluate whether AstraZeneca generated enough free cash flow to afford its dividend. It's hard to consistently pay out more cash than you generate without either borrowing or using company cash, so we'd wonder how the company justifies this payout level. Cash is slightly more important than profit from a dividend perspective, but given AstraZeneca's payments were not well covered by either earnings or cash flow, we are concerned about the sustainability of this dividend.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, February 19


News

DIRECTOR DEALINGS: AstraZeneca Non-Executive...

AZN AZN

(Alliance News) - AstraZeneca PLC said Wednesday that Non-Executive Director Michel Demare on ... (Alliance News) - AstraZeneca PLC said Wednesday that Non-Executive Director Michel Demare on Monday purchased around GBP51,000 in stock. Demare bought 700 shares at a price of GBP73.13 per share, though AstraZeneca did not disclose how many shares he now holds overall. Shares in the FTSE 100-listed pharmaceutical giant were up 1.4% at 7,625.00 pence on Wednesday afternoon in London. Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Read Full Details

Topics:
  • Business
  • Financial
  • Science
News

Here’s why Astrazeneca is one of the most expensive shares on the market

AZN AZN

Here’s why Astrazeneca is one of the most expensive shares on the market. It has long been understood that cheap stocks have a tendency to outperform expensive stocks in the stock market. While this is not true every single year, over almost every 3-year cycle in the stock market, cheap (or value) stocks outperform. This phenomenon has created the cult of 'Value Investing' born of the writings of Benjamin Graham and the amazing success of its arch proponent Warren Buffett. In the 4th edition of his groundbreaking investment research tome What Works on Wall St, O’Shaughnessy shows that composite value factors based on a mix of metrics dramatically beat the market over a multi-decade period.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, February 16


News

Why I’d avoid AstraZeneca shares and buy this FTSE 100 stock

AZN AZN

The AstraZeneca (LSE: AZN) share price has risen by more than 90% since May 2016 as investors have bought into CEO Pascal Soriot’s more focused strategy for the business. However, the shares dipped on Friday after Mr Soriot warned that 2020 earnings may be hit by the coronavirus outbreak. Core earnings of $3.50 per share were only slightly below broker forecasts of $3.59 per share. Although most companies use adjusted profits, I feel that AstraZeneca’s approach to calculating its core profits is aggressive and excludes some costs that should really be left in. The group’s core operating profit was $6,436m. But its reported operating profit, which includes all standard accounting costs, fell by 14% to $2,924m. This non-cash accounting charge relates to the gradual reduction in value of intellectual property such as patents, licences and software. As you can imagine, this kind of asset is a big part of a pharmaceutical business — AstraZeneca carries about $21bn of intangible assets on its balance sheet, reflecting historic spending.

Read Full Details

Topics:
  • Business
  • Financial

Saturday, February 15


News

AstraZeneca Announces Q4 Financial Results, Coronavirus Fears Weigh on Guidance

AZN AZN

Feb 14, 2020 8:14PM EST. AstraZeneca Announces Q4 Financial Results, Coronavirus Fears Weigh on Guidance | NASDAQ. AstraZeneca (NYSE: AZN) announced its fourth-quarter and 2019 full-year financial results on Friday morning. While the company reported impressive sales growth in a number of its top-selling drugs, investors are worried that the novel coronavirus outbreak could significantly eat away at the company's 2020 sales. Product sales accounted for the majority of this figure, around $6.25 billion, which is up a healthy 8.4% from Q4 2018. Another top performer for the company, a cancer drug called Imfinzi, is up 62% from Q4 2018 and brought in $424 million. The company's 2020 guidance expects high-single-digit to low-double-digit percentage increases in revenue assuming that the coronavirus doesn't last more than a few months.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial

Friday, February 14


News

Astrazeneca warns on 'unfavourable impact' from coronavirus outbreak

AZN AZN

Pharmaceutical giant AstraZeneca has warned that the impact from the coronavirus outbreak will hit the business for "up to a few months", making projections for the year ahead tricky, the company said. Bosses said the virus, called Covid-19, could particularly hit their business over rivals because China, which first reported the outbreak, is the firm's fastest-growing market. The warning came following a 15% rise in sales during the year to 23.5 billion dollars (£18 billion) - including a 35% sales boost in China alone. However, sales slowed in the final quarter of the year, rising just 9% compared with an 18% rise in the third quarter. Bosses at the Cambridge-based business added that sales in its three therapy areas of oncology, cardiovascular, renal and metabolism (CVRM) and respiratory grew during the year by 44%, 9% and 10% respectively.

Read Full Details

Topics:
  • Business
  • Health
  • Financial